List of Excipients in Branded Drug RYCLORA

Generic Drugs Containing RYCLORA

Company	Ingredient	NDC	Excipient
CARWIN PHARMACEUTICAL ASSOCIATES LLC	dexchlorpheniramine maleate	15370-150	CITRIC ACID MONOHYDRATE
CARWIN PHARMACEUTICAL ASSOCIATES LLC	dexchlorpheniramine maleate	15370-150	FD&C RED NO. 40
CARWIN PHARMACEUTICAL ASSOCIATES LLC	dexchlorpheniramine maleate	15370-150	GLYCERIN

What are the Most Frequently-Used Excipients in RYCLORA?

# Of NDCs	Excipient
1	CITRIC ACID MONOHYDRATE
1	FD&C RED NO. 40
1	GLYCERIN

RYCLORA Excipient Strategy and Commercial Opportunities

Last updated: September 3, 2026

RYCLORA is a prescription oral solution containing chlorpheniramine maleate, a first-generation antihistamine used for allergic conditions. Its active ingredient is long-established and inexpensive, so commercial differentiation depends on excipient performance, taste, dosing accuracy, packaging, pediatric usability, and manufacturing efficiency rather than molecule exclusivity. The strongest opportunities are sugar-free palatability, preservative optimization, low-volume dosing, unit-dose packaging, and improved supply reliability.

What is RYCLORA and how does its formulation compete?

RYCLORA contains chlorpheniramine maleate at 2 mg per 5 mL in an oral liquid formulation. The product is intended for oral administration and is labeled for allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, and allergic skin conditions.[1]

The known inactive-ingredient architecture includes:

Formulation function	RYCLORA excipient or excipient category	Commercial role
Sweetening	Sucralose	Reduces sugar load and supports pediatric acceptability
Humectancy and mouthfeel	Glycerin	Improves viscosity and oral texture
Preservation	Sodium benzoate	Controls microbial growth in an aqueous multidose product
Buffering	Citric acid and sodium citrate	Supports pH control and chemical stability
Vehicle	Purified water	Primary liquid carrier
Flavor	Flavor system identified in the product labeling	Masks chlorpheniramine bitterness

The principal technical problem is not solubilizing chlorpheniramine maleate. It is delivering a stable, microbiologically controlled liquid with acceptable taste while avoiding excessive viscosity, throat irritation, precipitation, flavor degradation, and dosing errors.

Chlorpheniramine is associated with sedation and anticholinergic effects. Excipient improvements cannot remove those pharmacologic risks, but they can improve administration and reduce noncompliance caused by poor taste or difficult dosing.

What excipients are most important in the RYCLORA formulation?

Sweeteners and taste masking

Sucralose is commercially useful because it provides high-intensity sweetness without adding a large sugar load. The main limitation is that sweetness alone may not sufficiently mask the bitter, medicinal, and lingering taste of chlorpheniramine.

Potential commercial improvements include:

• Sucralose combined with acesulfame potassium or a polyol system.
• Flavor layering using fruit, berry, citrus, or confectionary profiles.
• Bitter-blocking technologies based on flavor modifiers.
• Reduced aftertaste through pH and viscosity optimization.
• Taste-masked multiparticulate or granulated chlorpheniramine intermediates for reconstitution products.

A replacement sweetener must be evaluated for pH stability, microbial risk, osmolality, gastrointestinal tolerance, and regulatory acceptability. Polyols can improve mouthfeel but may create laxation concerns at higher daily intake. Aspartame would introduce phenylalanine labeling requirements and is less attractive for a broadly positioned pediatric product.

Preservation system

Sodium benzoate is a conventional preservative for acidic oral liquids. Its performance depends on pH because the unionized form has greater antimicrobial activity. The formulation therefore needs sufficient buffer capacity without making the product excessively acidic or unpleasant to taste.

Commercial opportunities include:

• Reducing sodium benzoate concentration through improved container-closure systems.
• Using potassium sorbate or a combined preservative system where compatibility supports it.
• Developing a preservative-free unit-dose product.
• Using microbial-reduction manufacturing and single-use packaging.
• Validating preservative effectiveness across the full in-use period.

Preservative changes create a meaningful regulatory burden. A reformulated product would require comparative stability, preservative-effectiveness testing, assay and degradation profiling, microbial limits, and packaging compatibility data. Preservative-free positioning is most commercially credible when paired with unit-dose packaging rather than a conventional multidose bottle.

Buffer system and pH control

Citric acid and sodium citrate provide a practical buffer system. The target pH must balance several competing requirements:

1. Chlorpheniramine chemical stability.
2. Sodium benzoate antimicrobial performance.
3. Flavor acceptability.
4. Container compatibility.
5. Minimization of degradation products.
6. Control of precipitation during storage.

A narrower pH operating range can create manufacturing and release-testing burdens. A robust formulation should tolerate normal raw-material variation and remain within specification after exposure to temperature cycling and long-term storage.

Glycerin and viscosity

Glycerin improves mouthfeel and can reduce the perception of a harsh aqueous solution. Excessive glycerin can make the product sticky, increase pour variability, and complicate accurate dosing from oral syringes.

A commercial development program should optimize:

• Dynamic and kinematic viscosity.
• Pour time from the marketed bottle.
• Oral-syringe withdrawal accuracy.
• Dose uniformity after shaking.
• Sedimentation or phase separation.
• Palatability at refrigerated and room temperatures.

A lower-viscosity product may have an advantage in pediatric administration, while a moderately higher-viscosity product may reduce splash and improve perceived quality. The best target depends on the intended dosing device.

What excipient-based commercial opportunities exist for RYCLORA?

Sugar-free, alcohol-free, and dye-free positioning

RYCLORA already has a strong platform for a clean-label positioning strategy because sucralose can support a sugar-free formulation. A product line could emphasize:

• Sugar-free.
• Alcohol-free.
• Dye-free.
• Gluten-free where substantiated.
• Preservative-free in unit-dose format.
• Pediatric oral-syringe compatibility.

These claims must be supported by the final formulation and labeling. They can support retail pharmacy differentiation, hospital formulary adoption, and caregiver preference without requiring a new active ingredient.

Pediatric presentation

A pediatric-ready presentation is the most practical growth opportunity. The product can be differentiated through:

• Oral syringes with 0.1 mL or 0.2 mL graduations.
• Bottle adapters that reduce spillage.
• Unit-dose cups for institutional use.
• Child-resistant closure with easy-open instructions for caregivers.
• Tamper-evident packaging.
• A flavor system tested in the intended age population.
• Reduced bottle fill volume to improve portability.

The dosing device is commercially important because oral-liquid medication errors commonly arise from confusion between teaspoons, tablespoons, and milliliters. A product sold with a calibrated oral syringe can support safer administration and create a device-centered competitive distinction.

Unit-dose and institutional supply

Hospitals, urgent-care centers, pediatric clinics, and long-term-care facilities may prefer unit-dose formats. A 5 mL or other clinically relevant dose presentation could reduce contamination risk and nursing preparation time.

Potential formats include:

Format	Primary customer	Commercial advantage
Multidose bottle	Retail pharmacy and home use	Lowest packaging cost
Bottle with oral syringe	Caregivers and pediatric patients	Better dosing accuracy
Unit-dose cup	Hospitals and clinics	Simplifies administration
Blow-fill-seal ampoule	Institutional and travel use	Low contamination risk
Stick pack or sachet	Limited-volume portable use	Convenience and reduced packaging weight
Powder for reconstitution	Supply-chain and stability-sensitive markets	Lower shipping weight and potential shelf-life benefits

The unit-dose opportunity is more defensible than a simple flavor change because it combines excipient selection, container-closure performance, filling process, and device usability.

What formulation patents could protect RYCLORA improvements?

A new chlorpheniramine formulation would not receive meaningful composition-of-matter protection for the old active ingredient. Protection would need to focus on a specific formulation or delivery configuration.

Potential claim categories include:

• Chlorpheniramine oral solution with a defined pH range.
• A specified preservative system with improved stability.
• A defined sweetener and flavor combination.
• A low-volume, high-concentration oral liquid.
• A preservative-free unit-dose composition.
• A formulation with a specified viscosity range.
• A container-closure system that maintains microbial quality.
• A powder-for-reconstitution formulation.
• A taste-masked chlorpheniramine dosage form.
• A dosing device integrated with the product.

Broad claims covering sucralose, glycerin, sodium benzoate, citric acid, or sodium citrate alone would likely face prior-art challenges because these excipients are standard pharmaceutical ingredients. Stronger patent positions would require unexpected stability, palatability, dose accuracy, preservative reduction, or manufacturing results supported by comparative data.

Trade-secret protection may be more valuable than patent protection for:

• Flavor ratios.
• Mixing order.
• Hydration and dissolution conditions.
• Deaeration parameters.
• Preservative addition sequence.
• Flavor-emulsion handling.
• Filling and hold-time controls.
• In-process pH adjustment.

What is the Orange Book and exclusivity status of RYCLORA?

RYCLORA does not have meaningful new-molecule exclusivity because chlorpheniramine maleate is an established antihistamine. Its commercial position is based on an approved oral-solution presentation rather than active-ingredient exclusivity.

The relevant regulatory pathways are:

Regulatory issue	RYCLORA impact
New chemical entity exclusivity	Not applicable to an old active ingredient
Orphan-drug exclusivity	Not applicable based on the labeled indications
Pediatric exclusivity	No product-specific extension should be assumed
Orange Book listing	Relevant only to patents listed for the approved product
ANDA competition	Possible if a generic applicant can demonstrate pharmaceutical equivalence
505(b)(2) competition	Possible for materially different formulations, devices, or delivery systems
Biosimilar risk	Not applicable because RYCLORA is a small-molecule drug
Formulation patent risk	Depends on any active, properly listed patents and claim scope

An ANDA competitor would generally target the same active ingredient, strength, dosage form, and route. A 505(b)(2) applicant could pursue a different excipient system, flavor, preservative profile, concentration, packaging format, or delivery device.

When does RYCLORA lose exclusivity and face generic entry?

The primary generic-entry risk is already present because the active ingredient is old and the product is an oral solution. A generic applicant does not need to reproduce every commercial attribute of RYCLORA if it can satisfy applicable FDA requirements for pharmaceutical equivalence, bioequivalence where required, quality, and labeling.

Potential launch scenarios are:

Scenario 1: Conventional generic oral solution

A competitor markets chlorpheniramine maleate oral solution with comparable strength and a different flavor or excipient profile. This is the highest-probability competitive threat.

Scenario 2: 505(b)(2) differentiated liquid

A sponsor develops a lower-volume, better-tasting, preservative-free, or device-integrated formulation. This product could compete without being an identical generic.

Scenario 3: Reconstitutable powder

A powder formulation could reduce shipping and storage costs, but it would introduce reconstitution instructions, dose-preparation risk, and additional stability requirements.

Scenario 4: Pediatric combination product

A chlorpheniramine product combined with another active ingredient could compete for allergy and cold-treatment use, although combination products face safety, labeling, and clinical-positioning constraints.

Paragraph IV risk is relevant only if a listed patent appears in the Orange Book and a generic applicant certifies that the patent is invalid, unenforceable, or will not be infringed. The existence and enforceability of any RYCLORA-specific listed patent should be assessed through the current FDA Orange Book record and relevant court dockets before a launch decision.[2]

Which companies could challenge RYCLORA commercially?

The main challengers are likely to come from three groups:

1. Generic manufacturers with oral-liquid capabilities.
2. Specialty pharmaceutical companies focused on pediatric and allergy products.
3. Contract development and manufacturing organizations offering taste-masked or unit-dose liquids.

Competitive pressure is likely to arise from products containing chlorpheniramine under generic labeling, legacy branded antihistamines, and alternative first-generation antihistamines such as brompheniramine and diphenhydramine. Second-generation antihistamines, including cetirizine, loratadine, and desloratadine, compete for the same allergy-treatment market but have different sedation and dosing profiles.

RYCLORA's strongest commercial defense is a reliable, easy-to-administer presentation rather than premium pricing based on the active ingredient.

How strong is the RYCLORA patent estate?

The patent estate is likely weak at the active-ingredient level and potentially moderate only for narrowly defined formulation or packaging innovations. A defensible improvement patent would need:

• A specific excipient combination.
• A defined concentration and pH range.
• Comparative stability or palatability data.
• A measurable reduction in preservative load or degradation.
• Improved dosing accuracy or microbial protection.
• A non-obvious result relative to known chlorpheniramine liquids.

A portfolio strategy could include one composition patent, one container-closure or unit-dose patent, and process claims covering manufacture. The commercial value of such patents would depend on whether the claims cover features that pharmacies, hospitals, or generic competitors cannot easily design around.

What manufacturing and supply-chain barriers affect RYCLORA?

The main manufacturing barriers are operational rather than molecule-specific:

• Maintaining uniform chlorpheniramine concentration throughout the batch.
• Preventing flavor loss during compounding and filling.
• Controlling pH after preservative and flavor addition.
• Managing microbial risk in aqueous multidose packaging.
• Avoiding extractables and leachables from plastic bottles and closures.
• Validating cleaning for sticky glycerin-containing formulations.
• Maintaining oral-syringe compatibility.
• Securing consistent flavor and preservative raw materials.
• Demonstrating stability after opening.

A dual-source strategy for chlorpheniramine maleate, sodium benzoate, flavor components, and packaging materials could reduce interruption risk. The most vulnerable input may be the proprietary flavor system rather than the active ingredient.

What licensing opportunities exist for RYCLORA excipient technology?

Licensing opportunities are strongest in platform technologies that can apply across multiple pediatric liquids. Relevant assets include:

• Bitter-blocking flavor systems.
• Preservative-reduction technology.
• Unit-dose blow-fill-seal manufacturing.
• Oral-syringe and bottle-adapter systems.
• Taste-masked liquid or powder intermediates.
• Stability-enhancing packaging.
• High-throughput low-volume liquid filling.

A licensee would likely value a technology more if it can support several antihistamines, analgesics, antibiotics, and pediatric supplements. A RYCLORA-only formulation license would have a smaller addressable market because the active ingredient is generic and price competition is substantial.

Key Takeaways

• RYCLORA is a chlorpheniramine maleate oral solution whose commercial differentiation depends on formulation execution.
• The most valuable excipient opportunities are taste masking, preservative optimization, viscosity control, and pH stability.
• Sugar-free, alcohol-free, dye-free, and pediatric-ready positioning can support premium differentiation.
• Unit-dose and oral-syringe presentations offer stronger commercial protection than a simple flavor change.
• RYCLORA has no biologic component, so biosimilar risk is not relevant.
• Generic entry is possible through conventional ANDA competition, while materially different formulations may use the 505(b)(2) pathway.
• Broad excipient patents would likely be vulnerable to prior art. Narrow claims supported by comparative data are more defensible.
• Manufacturing, packaging, microbial control, and flavor supply are the principal operational barriers.
• Platform licensing is more attractive than a single-product license because the same excipient technology can apply across pediatric liquid medicines.

FAQs About RYCLORA Excipient Strategy

Can RYCLORA be reformulated without changing its active ingredient?

Yes. A sponsor could change the sweetener, flavor, buffer, preservative, viscosity modifier, concentration, packaging, or dosing device while retaining chlorpheniramine maleate.

Is a preservative-free RYCLORA formulation commercially feasible?

Yes, particularly in a unit-dose or other single-use package. A preservative-free multidose bottle would require stronger microbial-control and in-use stability justification.

Would a new RYCLORA flavor receive patent protection?

A flavor alone would usually provide weak protection. Patentability would improve if the flavor system produces an unexpected reduction in bitterness or improves stability in a defined formulation.

Could a RYCLORA competitor use different excipients?

Yes. A generic or 505(b)(2) competitor may use a different excipient system if the product meets FDA requirements for quality, performance, safety, and labeling.

Is RYCLORA suitable for a high-concentration, low-volume formulation?

Potentially. A low-volume product could improve portability and dosing convenience, but it would require evaluation of solubility, taste intensity, viscosity, dose uniformity, and administration-device accuracy.

References

1. DailyMed. (n.d.). RYCLORA- chlorpheniramine maleate solution: Prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly purified synthetic peptides.
4. U.S. Food and Drug Administration. (2022). Inactive ingredient database.
5. U.S. Food and Drug Administration. (2016). Q1A(R2) stability testing of new drug substances and products.